Incannex Healthcare (IXHL) 10-K Summaries & Annual Filing History
Review Incannex Healthcare Inc. (IXHL) 10-K filings from 2023 through the latest annual report, including business, financial performance, risks, and liquidity.
Key takeaway
Year ended Jun 30, 2024 · FY2024 10-K
Incannex Healthcare is a development-stage pharmaceutical company with minimal revenue and significant losses. The company faces substantial doubt about its ability to continue as a going concern due to ongoing negative cash flows and limited cash reserves.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$12K
Revenue reported for the fiscal year.
Operating income
-$30M
Income from operations reported for the year.
Net income
-$18.5M
Net income reported for the year.
Operating cash flow
-$15.8M
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2020 | $604.9K | n/a |
| Jun 30, 2021 | $1.9M | +213.7% |
| Jun 30, 2024 | $12K | -99.4% |
Business overview
The company focuses on research and development to advance its drug candidates into later stages, including through the acquisition of APIRx. It has incurred net losses since inception and expects to continue investing heavily in R&D activities.
Financial performance
Revenue for the reported period was minimal, while operating loss was substantial. Net loss improved compared to the prior year, primarily due to a decrease in acquisition-related expenses. Operating cash outflows increased, reflecting higher spending on operations.
Material risks
The company has identified a material risk that it may not be able to continue as a going concern, given its history of losses, negative operating cash flows, and low cash balance. Future operations are dependent on the company's ability to obtain additional financing.
Liquidity and capital
Historically, the company has funded its operations through equity sales, option exercises, and tax grants. With a modest cash position and expected continued negative cash flows, the company will need to raise additional capital to meet its obligations.
What to watch
Monitor the company's success in securing additional financing or achieving a development milestone that could alleviate its liquidity concerns.